Phase Forward Inc. swings to a fourth-quarter loss, despite posting a 22 percent increase in Q4 sales, as its pays off a buying spree.
Phase Forward Inc. (NSDQ:PFWD) paid a small price for success during the fourth quarter, as mounting expenses from a flurry of acquisitions swung it into the black.
The Waltham, Mass.-based clinical data management provider reported a net loss of $68,000 for the three months ended Dec. 30, 2009, compared to more than $2 million in net income for the same period in 2008. Full-year net income fell by 38 percent to $8 million, compared with nearly $14 million during Q4 2008.
Officials attributed the bottom-line drop to non-cash expenses including a $2.3 million impairment charge and a $700,000 increase in the amortization of intangible assets resulting from acquisitions.*
Despite the Q4 dip, there was plenty for company officials to celebrate, particularly a 22 percent increase in sales during the quarter and 25 percent sales boost for the full year.
Phase Forward reported $58 million in fourth-quarter sales, compared to $48 million for the same period last year, and $213 million in sales during 2009, compared with $170 million during 2008. The company was particularly successful in driving up its service sales, which rose 31 percent during the year.
PFWD spent a bit of its nest egg to try and shore up its share price, initiating a $40 million stock repurchasing program during the fourth quarter. The company's total cash, cash equivalents and investments were $135.5 million as of Dec. 31, a decrease of $11.7 million from $147.2 million on hand at the end of the prior quarter.
Phase Forward said it expects to post earnings of $56 million to $57.5 million on sales of $240 million to $248 million during the first quarter.
*Correction, Feb. 5, 2010: This article originally referred to a trio of acquisitions in November that were, in fact, contracts rather than buyouts. Return to the corrected sentence.
President Barack Obama took to the stump in Ohio to press for the passage of healthcare reform.
Medical device maker Z-Medica of Wallingford, Conn., pledges $25,000 to the Yellow Ribbon program at...
New Haven-based cancer therapy diagnostics firm HistoRx Inc. lands a $1.5 million loan from...
EnteroMedics Inc. is preparing for another clinical trial of its Maestro neurostimulation implant in...